The iconic rise of Sildenafil presented a considerable opportunity for investors , but its period has ended, creating a challenging landscape. Off-brand versions have entered the market , cutting into sales and putting pressure on profit yields. While leading healthcare companies hold a stake in this area, the future seems clouded by fierce competi